{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T22:45:20Z","timestamp":1782168320407,"version":"3.54.5"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"am","delay-in-days":414,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.therap.2020.05.002","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T11:40:15Z","timestamp":1588851615000},"page":"371-379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"title":["\u201cOff-label\u201d use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers"],"prefix":"10.1016","volume":"75","author":[{"given":"Alexandre","family":"G\u00e9rard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Romani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Fresse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Viard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nad\u00e8ge","family":"Parassol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Granvuillemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Chouchana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Rocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milou-Daniel","family":"Drici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2020.05.002_bib0240","series-title":"COVID-19 Coronavirus pandemic","author":"Worldometer","year":"2020"},{"key":"10.1016\/j.therap.2020.05.002_bib0245","series-title":"WHO Director-General's opening remarks at the media briefing on COVID-19","author":"Adhanom","year":"2020"},{"key":"10.1016\/j.therap.2020.05.002_bib0250","doi-asserted-by":"crossref","first-page":"117477","DOI":"10.1016\/j.lfs.2020.117477","article-title":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19","volume":"248","author":"Elfiky","year":"2020","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.therap.2020.05.002_bib0255","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"issue":"3","key":"10.1016\/j.therap.2020.05.002_bib0260","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.therap.2020.05.002_bib0265","doi-asserted-by":"crossref","DOI":"10.1097\/FJC.0000000000000836","article-title":"Cardiovascular considerations in treating patients with coronavirus (COVID-19)","author":"Dixon","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.therap.2020.05.002_bib0270","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2020.05.002_bib0275","article-title":"A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","author":"Cortegiani","year":"2020","journal-title":"J Crit Care"},{"issue":"1","key":"10.1016\/j.therap.2020.05.002_bib0280","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discov Ther"},{"key":"10.1016\/j.therap.2020.05.002_bib0285","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4742","article-title":"Treating COVID-19-off-label drug use, compassionate use, and randomized clinical trials during pandemics","author":"Kalil","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2020.05.002_bib0290","article-title":"D\u00e9cret no\u00a02020-314\u00a0du 25\u00a0mars 2020\u00a0compl\u00e9tant le d\u00e9cret no\u00a02020-293\u00a0du 23\u00a0mars 2020\u00a0prescrivant les mesures g\u00e9n\u00e9rales n\u00e9cessaires pour faire face \u00e0 l\u2019\u00e9pid\u00e9mie de COVID-19\u00a0dans le cadre de l\u2019\u00e9tat d\u2019urgence sanitaire","volume":"0074","author":"Journal Officiel de la R\u00e9publique Fran\u00e7aise no\u00a00074\u00a0du 26\u00a0mars 2020","year":"2020","journal-title":"Journal Officiel de la R\u00e9publique Fran\u00e7aise"},{"key":"10.1016\/j.therap.2020.05.002_bib0295","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-0888-2","article-title":"The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin","author":"Chorin","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.therap.2020.05.002_bib0300","series-title":"French drug-surveillance specialist highlights hydroxychloroquine risks","author":"Gauthier-Villars","year":"2020"},{"key":"10.1016\/j.therap.2020.05.002_bib0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.acvd.2020.04.001","article-title":"Response to the editorial \u201cCOVID-19 in patients with cardiovascular diseases\u201d: Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: a potential risk of Torsades de Pointes","author":"Funck-Brentano","year":"2020","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.therap.2020.05.002_bib0310","series-title":"COVID-19: reminder of risk of serious side effects with chloroquine and hydroxychloroquine","author":"EMA","year":"2020"},{"key":"10.1016\/j.therap.2020.05.002_bib0315","series-title":"Hydroxychloroquine or chloroquine for COVID-19: drug safety communication\u00a0\u2013\u00a0FDA cautions against use outside of the hospital setting or a clinical trial due to risk of heart rhythm problems","author":"FDA","year":"2020"},{"issue":"10","key":"10.1016\/j.therap.2020.05.002_bib0320","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40264-018-0689-4","article-title":"Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature","volume":"41","author":"Chatre","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2020.05.002_bib0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.therap.2020.02.022","article-title":"Uses of pharmacovigilance databases: an overview","author":"Bihan","year":"2020","journal-title":"Therapies"},{"issue":"6","key":"10.1016\/j.therap.2020.05.002_bib0330","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.therap.2019.09.004","article-title":"Pharmacovigilance\u00a0\u2013\u00a0The next chapter","volume":"74","author":"Moore","year":"2019","journal-title":"Therapies"},{"issue":"2","key":"10.1016\/j.therap.2020.05.002_bib0335","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.therap.2016.02.010","article-title":"Causality assessment in pharmacovigilance: the French method and its successive updates","volume":"71","author":"Miremont-Salam\u00e9","year":"2016","journal-title":"Therapie"},{"issue":"21","key":"10.1016\/j.therap.2020.05.002_bib0340","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1161\/CIRCULATIONAHA.118.033943","article-title":"Determination and interpretation of the QT interval","volume":"138","author":"Vink","year":"2018","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.therap.2020.05.002_bib0345","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jacc.2008.12.014","volume":"53","author":"Rautaharju","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.therap.2020.05.002_bib0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.therap.2020.05.001","article-title":"Adverse drug reactions of hydroxychloroquine: analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data","author":"Grandvuillemin","year":"2020","journal-title":"Therapies"},{"issue":"5","key":"10.1016\/j.therap.2020.05.002_bib0355","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Underreporting of adverse drug reactions","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2020.05.002_bib0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.medmal.2020.03.006","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection","author":"Molina","year":"2020","journal-title":"Med Mal Infect"},{"issue":"10","key":"10.1016\/j.therap.2020.05.002_bib0365","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.hrthm.2015.05.027","article-title":"Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current if: novel electrophysiological insights and therapeutic potential","volume":"12","author":"Capel","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.therap.2020.05.002_bib0370","series-title":"Sudden cardiac death: a handbook for clinical practice","first-page":"177","article-title":"Drug-induced sudden death","author":"Roden","year":"2005"},{"issue":"1","key":"10.1016\/j.therap.2020.05.002_bib0375","first-page":"185","article-title":"Cardiac K+ channels and drug-acquired long QT syndrome","volume":"55","author":"Drici","year":"2000","journal-title":"Therapie"},{"issue":"1","key":"10.1016\/j.therap.2020.05.002_bib0380","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0022-3565(24)29555-0","article-title":"Blockade of currents by the antimalarial drug chloroquine in feline ventricular myocytes","volume":"297","author":"S\u00e0nchez-Chapula","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.therap.2020.05.002_bib0385","doi-asserted-by":"crossref","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.therap.2020.05.002_bib0390","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1473-3099(07)70187-1","article-title":"Cardiotoxicity of antimalarial drugs","volume":"7","author":"White","year":"2007","journal-title":"Lancet Infect Dis"},{"issue":"9460","key":"10.1016\/j.therap.2020.05.002_bib0395","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(05)17950-1","article-title":"Blockade of HERG channels by HIV protease inhibitors","volume":"365","author":"Anson","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.therap.2020.05.002_bib0400","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0092-8674(95)90340-2","article-title":"A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel","volume":"81","author":"Sanguinetti","year":"1995","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.therap.2020.05.002_bib0405","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2125.2008.03332.x","article-title":"Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional study","volume":"67","author":"Charbit","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"18","key":"10.1016\/j.therap.2020.05.002_bib0410","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJMp1302726","article-title":"Cardiovascular risks with azithromycin and other antibacterial drugs","volume":"368","author":"Mosholder","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.therap.2020.05.002_bib0415","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s12012-017-9401-7","article-title":"Electrophysiologic studies on the risks and potential mechanism underlying the proarrhythmic nature of azithromycin","volume":"17","author":"Zhang","year":"2017","journal-title":"Cardiovasc Toxicol"},{"issue":"20","key":"10.1016\/j.therap.2020.05.002_bib0420","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jama.280.20.1774","article-title":"Cardiac actions of erythromycin: influence of female sex","volume":"280","author":"Drici","year":"1998","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.therap.2020.05.002_bib0425","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.therap.2020.05.002_bib0430","first-page":"155","article-title":"Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: a narrative review based on the study of case reports","volume":"1","author":"Hancox","year":"2013","journal-title":"Ther Adv Infect Dis"},{"issue":"8","key":"10.1016\/j.therap.2020.05.002_bib0435","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2165\/00002018-200124080-00002","article-title":"Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome","volume":"24","author":"Drici","year":"2001","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2020.05.002_bib0440","doi-asserted-by":"crossref","unstructured":"Chen D, Li X, Song Q, Hu C, Su F, Dai J. Hypokalemia and clinical implications in patients with coronavirus disease 2019 (COVID-19). 2020. 10.1101\/2020.02.27.20028530.","DOI":"10.1101\/2020.02.27.20028530"},{"issue":"6","key":"10.1016\/j.therap.2020.05.002_bib0445","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.hrthm.2005.02.011","article-title":"Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one","volume":"2","author":"Viskin","year":"2005","journal-title":"Heart Rhythm"},{"issue":"2","key":"10.1016\/j.therap.2020.05.002_bib0450","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.amjmed.2018.08.025","article-title":"The computerized ECG: friend and foe","volume":"132","author":"Smulyan","year":"2019","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.therap.2020.05.002_bib0455","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40264-020-00933-4","article-title":"Chloroquine for COVID-19 infection","volume":"43","author":"Moore","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2020.05.002_bib0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.mayocp.2020.03.024","article-title":"Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19)","author":"Giudicessi","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.therap.2020.05.002_bib0465","doi-asserted-by":"crossref","unstructured":"Wang J, Yu L, Li K. Benefits and risks of chloroquine and hydroxychloroquine in the treatment of viral diseases: a meta-analysis of placebo randomized controlled trials. 2020. 10.1101\/2020.04.13.20064295.","DOI":"10.1101\/2020.04.13.20064295"},{"key":"10.1016\/j.therap.2020.05.002_bib0470","series-title":"Estimating the burden of SARS-CoV-2 in France","author":"Salje","year":"2020"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720300913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720300913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:54:10Z","timestamp":1758567250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595720300913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0040595720300913"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2020.05.002","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cOff-label\u201d use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}